Clinical Research Directory
Browse clinical research sites, groups, and studies.
The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy
Sponsor: Fujian Cancer Hospital
Summary
To explore the efficacy and safety of radiotherapy followed by PD-1+ standard chemotherapy in the first-line treatment of initial unresectable rectal cancer liver metastases
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2023-05-01
Completion Date
2026-05-01
Last Updated
2022-12-07
Healthy Volunteers
No
Conditions
Interventions
PD-1
Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks
SCRT
Radiotherapy dose: 5×5 Gy
Bevacizumab
Participants will receive bevacizumab,5mg/kg,intravenously over 60 - 90 minutes, day 1 of every 2 weeks
Oxaliplatin
Participants will receive Oxaliplatin,85mg/m2,day1
Calcium folinate
Participants will receive calcium folinate ,400mg/m2,day1
5-fluorouracil
Participants will receive 5-fluorouracil ,400mg/m2,day1